ChroMedX Announces HemoPalm Trademark and Intellectual Property Update
October 23, 2014
ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the trademark for the Company's patented HemoPalm technology has been allowed by the United States Patent and Trademark Office and will be officially registered when the HemoPalm is released commercially.
The HemoPalm technology is currently covered by two issued and one pending patent. The pending patent will be filed internationally in spring 2015, with the intent to extend the patent protection term in the US, and to seek patent protection at least in Europe and Asia for the extended term.
"ChroMedX continues to build on a strong foundation of intellectual property detailing the Company's novel in-vitro diagnostic and point-of-care testing systems. We are pleased to make this announcement and look forward to the official registration of the HemoPalm trade mark. " said Dr. Wayne Maddever, P.Eng, President & CEO of ChroMedX Corp.
Furthermore, ChroMedX has recently been assigned U.S. patent 7,807,450 which covers various aspects of the Company's Plasma Extraction Cartridge, a novel device for the separation of plasma from whole blood at the point of collection.
The AUF (Automatic Ultra Filtration) patent application was filed internationally and earlier this year a very favorable written response was issued by the international searching authority. Last week on behalf of ChroMedX, the IP law firm Bereskin & Parr filed a demand for international preliminary examination.
A list of issued and pending patents can be found on the company's website here: http://www.chromedx.com/intellectual-property/
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
The Company recently announced the engagement of Mr. Marco Witteveen of the Netherlands as a Business Development Advisor to assist the Company in the global commercialization of its innovative point of care and in vitro diagnostics technologies.
President, CEO & Director
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com